What is IMIDomics?
IMIDomics, Inc. is a privately held global biotechnology company established in Barcelona, Spain, in 2015. Headquartered in San Rafael, California, the company is dedicated to the discovery and development of new medicines targeting immune-mediated inflammatory diseases (IMIDs). Founded by Dr. Sara Marsal and Dr. Richard M. Myers, IMIDomics leverages deep scientific expertise to address unmet needs in rheumatology and related inflammatory conditions. The company's focus on IMIDs positions it within a critical area of medical research, aiming to translate scientific insights into tangible therapeutic solutions for patients suffering from debilitating autoimmune disorders.
How much funding has IMIDomics raised?
IMIDomics has raised a total of $16.5M across 1 funding round:
Series A
$16.5M
Series A (2021): $16.5M with participation from DNS Capital, Tao Capital Management, Bristol-Myers Squibb, and The Pritzker Organization
Key Investors in IMIDomics
DNS Capital
DNS Capital is an investment office focused on long-term investments, fostering relationships with entrepreneurs to create lasting value. They aim to partner with those seeking to make a positive impact.
Tao Capital Management
Tao Capital Management operates within the Venture Capital & Private Equity sector, focusing on strategic investments to drive growth and innovation in its portfolio companies.
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and manufacturing prescription medications for serious patient needs, with expertise in oncology, cardiovascular disease, and immunoscience.
What's next for IMIDomics?
With the recent influx of capital, IMIDomics is poised to accelerate its research and development pipeline. The company's strategic objective is likely to advance its lead drug candidates through clinical trials, expand its research capabilities, and potentially forge new partnerships within the biopharmaceutical ecosystem. This latest funding round, characterized as major enterprise-level financing, suggests a strong investor confidence in IMIDomics' scientific approach and its potential to deliver impactful treatments for immune-mediated inflammatory diseases, paving the way for future growth and market expansion.
See full IMIDomics company page
